VFA
AKBA icon

Virtus Fund Advisers’s Akebia Therapeutics AKBA Stock Holding History

Virtus Fund Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$349K Buy
+23,459
New +$389K ﹤0.01% 403
2014
Q3 		– Sell
-668
Closed -$19K – 1178
2014
Q2 		$19K Buy
+668
New +$16.1K ﹤0.01% 2460

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Virtus Fund Advisers's AKBA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Akebia Therapeutics (AKBA) in Q4 2017: 23,459 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #403 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in AKBA as recently as Q2 2014.

Virtus Fund Advisers first reported a position in AKBA in Q2 2014 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold AKBA as of Q4 2017.

  • Virtus Fund Advisers held 23,459 shares of Akebia Therapeutics worth $349K as of Q4 2017.
  • Akebia Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Akebia Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #403 holding.
  • Virtus Fund Advisers first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.